Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (January 2022)
27 slides from Myomo's investor presentation, January 2022
Slide 1: Conquering Upper Limb Paralysis with Wearable Medical Robotics
Paul R. Gudonis, Chairman and CEO David Henry, CFO Investor Presentation January 2022 Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Compan
Slide 3: Company Overview
Company Overview We design, manufacture and provide Only commercially available device of its the MyoPro™, a wearable medical kind with FDA registration, government robotic device that restores and private reimbursement and CE mark movement and function of paralyzed arms and hands Lightweight and po
Slide 4: Investment Highlights: Market Leader in New Product Category
Investment Highlights: Market Leader in New Product Category ➢ Creating a new product category for this large unmet medical need - Patient Population with Chronic Arm Paralysis = Approx. 3M in US - New Incidences in US each year = Approx. 250K due to new strokes, other neuro conditions - Worldwide n
Slide 5: Company Updates: January 2022
Company Updates: January 2022 ➢ Announced Progress on Insurance Reimbursement issue from November 2021 - A major payer started to deny post-delivery payments on claims for pre-authorized units - 90% of these claims have now been paid, and others are in process - Payer has stated to us that they are
Slide 6: Continuing the Digital Transformation of Myomo Operations
Continuing the Digital Transformation of Myomo Operations Faster --------- Lower Cost --------- More Convenient Lead Generation Patient Evaluation Product Measurement Fabrication & Assembly Post Delivery Support Past In-person hospital In-person screening day In-person casting Outsourced, manual Reh
Slide 7: If You Know 100 People, You Probably Know Someone who needs a MyoPro
If You Know 100 People, You Probably Know Someone who needs a MyoPro NYSE American: MYO 7
Slide 8: A Large Unmet Need: Sizing the Market Opportunity
A Large Unmet Need: Sizing the Market Opportunity Prevalence Population Addressable Market (Chronic Arm Paralysis) New 6 - 12 mos. incidences: Rehab Therapy Stroke US: 800,000 Spinal Cord Injury Living Medically Insurance Patient strokes / yr. Brachial Plexus At Home Qualified Reimbursement Interest
Slide 9: Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t
Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t Current Treatment Options Rehabilitation: The Medical Need: ➢ Occupational therapy ➢ Static bracing A lightweight, portable ➢ Saebo ➢ Electrical stimulation device to restore (Bioness) ➢ Stationary robotics function for use
Slide 10: MyoPro Users and Value Propositions
MyoPro Users and Value Propositions Bettina Lucinda Igal Dave • Skiing accident @ age • Stroke during brain tumor operation • No use of right arm, • US veteran, arm 15 led to brachial plexus • Restored use of arm and hand 4 years post-stroke paralyzed due to stroke injury • Able to return to work •
Slide 11: Myomo’s Technology Leadership
Myomo’s Technology Leadership Operating at the Intersection of 3 Neuroscience Robotics Scientific and Engineering Disciplines • Brain-Computer Interface via EMG Sensors Software • Wearable Robotics • Advanced Control Algorithms • Patent Portfolio For EMG-Controlled Orthotics Extended to 2039 • New P
Slide 12: MyoPro Powered Arm Brace: How it Works
MyoPro Powered Arm Brace: How it Works Brain Movement Signal Signal EMG Processing Sensor NYSE American: MYO 12
Slide 13: Competitive Positioning
Competitive Positioning Prosthetics Orthotics (Braces) Only commercially available upper limb product line to restore function Upper Upper Limb Limb Products Products Foot Drop Stance Control Exoskeletons Wheelchair Lower Limb Lower Products Limb Products Unit Volume NYSE American: MYO 13
Slide 14: Trends in Healthcare Fueling Myomo’s Growth
Trends in Healthcare Fueling Myomo’s Growth ➢ Large and Growing Pool of Patient Candidates - Stroke Incidence increases with Aging Population, Underlying Health Conditions ➢ Centralized Decentralized Patient Care - From Rehab Clinic to At-home Use ➢ In-person Visits Telehealth - Enabled by Broadband
Slide 15: Over-Arching Strategic Goal = Market Penetration
Over-Arching Strategic Goal = Market Penetration Improve the Lives of a Growing Number of Patients each year by… ➢ Increasing Market Awareness & Candidate Pipeline via Increased Advertising - Cost-effective CAC per Pipeline Add leading to ASP = $35,000 @ 70% + gross margin ➢ Utilizing Digital Techno
Slide 16: Go to Market Approach: Direct Billing and Provider
Go to Market Approach: Direct Billing and Provider Lead Delivery Generation Reimbursement & & Approval Payment Evaluations Mass Customization Common Robotic Components Custom Fabricated MyoPro NYSE American: MYO 14
Slide 17: Filling the Pipeline via Digital Marketing and Telehealth
Filling the Pipeline via Digital Marketing and Telehealth Online Marketing Ads Social Media TeleHealth Evaluations Digital marketing to patients and families (B2C) 700,000+ likes on TikTok Moved online: faster, more convenient, less costly NYSE American: MYO 17
Slide 18: Increasing # of Payers reimbursing cost of a MyoPro
Increasing # of Payers reimbursing cost of a MyoPro Commercial Payers Military Medicare • Approvals on a case- by- case basis • Approved for Vets • New HCPCS codes in • > 80% of Pipeline consists • > 40 VAMC’s have 2019 of patients with insurers ordered MyoPro’s • Medicare Advantage who have authori
Slide 19: Myomo Now an Accredited Medicare Provider
Myomo Now an Accredited Medicare Provider ➢ Once coverage and fee are determined by CMS, Myomo will be able to provide the MyoPro to Medicare Part B patients in 39 states ➢ Working on becoming certified in the remaining states ➢ Working on becoming a provider for patients covered by state Medicaid p
Slide 20: International Update: Activity in Key Markets
International Update: Activity in Key Markets Pipeline growing in UK China JV company established - 19.9% Equity Interest for MYO shareholders China patents issued Next: Funding and launch of JV Operations Australia O&Ps starting to order German O&Ps ordering MyoPro’s; SHI now covers 52% of populati
Slide 21: MyoPro Delivery and Payment: Shift to Direct Billing
MyoPro Delivery and Payment: Shift to Direct Billing Revenue Percent by Channel • Emphasis on the direct billing channel results in higher average selling price 100% and higher gross margin per unit 80% • International revenue expected to grow in the future as we capitalize on favorable coverage pol
Slide 22: Backlog and Pipeline: Authorization to Revenue
Backlog: Authorization to Revenue - Near-Term Indicator Pipeline: Successful Evaluation to Authorization – Longer-Term Indicator Backlog Pipeline 200 177 1000 940 898 920 180 162 160 900 160 768 800 741 756 131 711 386 277 331 140 120 118 700 594 228 209 120 600 192 307 100 500 193 80 80 400 60 53 6
Slide 23: Revenue Growth: 2016- Q3 2021
Revenue Growth: 2016- Q3 2021 Quarterly Revenue Annual Revenue $M 5,000,000 4,500,000 9.8 4,000,000 3,500,000 7.6 3,000,000 2,500,000 2,000,000 3.8 1,500,000 2.4 1,000,000 1.6 1.0 500,000 0 1Q 2Q 3Q 4Q 2016 2017 2018 2019 2020 YTD 2021 2016 2017 2018 2019 2020 2021 NYSE American: MYO 23
Slide 24: P&L and Key Balance Sheet Metrics
P&L and Key Balance Sheet Metrics P&L Actual Actual YTD Actual Actual Key Balance Sheet Metrics ($000's) Q3'21 Q3'20 2021 2020 Actual Actual Revenue $ 4,384 $ 1,926 $ 9,825 $ 7,583 ($000's) Q3'21 Q2'21 COGS 1,110 855 2,635 2,600 Gross Profit 3,274 1,071 7,190 4,983 Cash $ 12,607 $ 13,772 Gross Margi
Slide 25: Leadership Team & Board of Directors
Leadership Team & Board of Directors Management Team Members Board of Directors & Advisors Paul R. Gudonis Dr. Harry Kovelman Ross D. Zafonte, DO Chairman & CEO Chief Medical Officer Chair, SAB Scaled multiple tech co’s, largest from Track record of expanding patent Harvard Med. School, $5M to $1.2B
Slide 26: Near Term Catalysts
Near Term Catalysts Positioned for strong revenue growth in 2022: New Product Announcements: • Focus on growing pipeline and backlog • Lower costs with new MyoPro 2+ version • Efforts to improve “win rate” with payers. • Restarting MyoPal Development • Additional payers covering the cost of MyoPro N
Slide 27: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 NYSE American: MYO 27